Roivant Sciences (ROIV)
Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies. I...
- Open
- 36.100
- High
- 36.270
- Low
- 35.705
- Prev. Close
- 36.300
- Volume
- 571.81K
- Turnover
- 20.60M
- Avg Price
- 36.023
- Bid/Ask Ratio
- -50.80%
- Amplitude
- 1.56%
- 52wk High
- 37.970
- Volume Ratio
- 0.93
- Turnover Ratio
- 0.10%
Roivant Sciences Analyst Rating
View moreForecast & Rating
Aug 20, 2026Price forecast
$41.8216.23%
Forecast & RatingStrong buy
12analysts
- Strong buy75.00%
- Buy16.67%
- Hold8.33%
- Sell0.00%
- Strong sell0.00%
News
- Weekly Review · 2 days ago, 12:38 AM
Weekly Recap | Roivant Sciences +0.28%, most brokers rate it buy
- Market Beat · 2 days ago, 10:07 PM
Mayukh Sukhatme Sells 17,519 Shares of Roivant Sciences (NASDAQ:ROIV) Stock
- PUBT · 2 days ago, 08:01 PM
Roivant President, CIO Mayukh Sukhatme disposes of common shares worth $12.47 million
- Market Beat · Aug 19 at 04:22 AM
Roivant Sciences (NASDAQ:ROIV) Insider Sells 284,707 Shares
- TradingView · Aug 18 at 08:10 PM
Roivant Sciences President & CIO Sold Shares Worth Over $24M
- PUBT · Aug 18 at 08:00 PM
Roivant President, CIO Mayukh Sukhatme disposes of USD 24.12 million in common shares
